GoldenGolden
Advanced Search
Casma Therapeutics

Casma Therapeutics

Casma Therapeutics is a company that has a research community and uses its understanding of research to develop novel therapeutics to capture disease causing targets.

Casma Therapeutics is a company that has a research community and uses its understanding of research to develop novel therapeutics to capture disease causing targets, improve lysosomal degradation and improve membrane integrity.

Timeline

September 2020
Casma Therapeutics raises a $50,000,000 series B round from Eventide Asset Management, Schroder Adveq, The Column Group and Third Rock Ventures.
May 2019
Casma Therapeutics raises a $370,000 grant.
May 2018
Casma Therapeutics raises a $58,500,000 series A round from Third Rock Ventures.

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Third Rock Ventures Launches Casma Therapeutics with $58.5 Million Investment to Harness the Cellular Process of Autophagy to Develop Breakthrough Therapies

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
December 1, 2020
BioSpace
Casma Therapeutics, Inc. and Vipergen ApS announced today the signing of a drug discovery agreement. Under the terms of the agreement, Vipergen will apply its proprietary high-fidelity DNA-encoded library (DEL) technology platform to discover novel small-molecule drug leads against a broad range of undisclosed Casma discovery targets
November 17, 2020
BioSpace
Casma Therapeutics Appoints Nagesh Mahanthappa, Ph.D., MBA, to Board of Directors - read this article along with other careers information, tips and advice on BioSpace
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.